Kurin, Inc. Receives Allowance from United States Patent and Trademark Office for Patent on Innovative Blood Culture Collection Device
SAN DIEGO--(BUSINESS WIRE)--Jul 17, 2018--Kurin, Inc., the inventor and manufacturer of 510(k)-cleared Kurin® blood culture collection sets, announced today that the United States Patent Office allowed its patent application and has issued U.S. Patent No. 10,010,282. The Kurin blood culture collection set is a replacement for traditional collection sets, introducing technology to divert skin contaminants while preserving the standard blood culture collection technique for clinicians.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20180717005141/en/
Kurin blood culture collection sets divert skin microbes in the initial blood specimen that may contaminate blood cultures and cause false positive test results. (Photo: Business Wire)
Like regular blood culture sets, Kurin sets include a butterfly needle for venipuncture or luer connection to a peripheral catheter and a needle for filling a culture bottle. Unique to Kurin is the Kurin Lock™ blood sequestration device, which includes a chamber for diversion of the initial aliquot of blood that often contains skin contaminants from the venipuncture site. After diversion, the Kurin Lock automatically sends the blood flow around the sequestration chamber through another channel into the culture bottle.
“This additional patent is the next step in building intellectual property protection for our unique blood diversion technology,” said Bob Rogers, Inventor and Chief Executive Officer. “As clinical results continue to prove the effectiveness of Kurin, this U.S. patent further strengthens our position in the market. The simplicity of this product is critical to caregiver compliance and compliance is the key to improving clinical outcomes. With no need for manual manipulation, a Kurin set makes it effortless for clinicians to incorporate diversion, a proven method of lowering contaminated blood cultures, into their routine collection process.”
Blood culture diversion technology can benefit hospitals and health systems, which suffer significant financial losses due to false positive blood culture results. When sepsis is erroneously indicated, unnecessary treatment and testing may ensue. Furthermore, patients who receive false positive blood culture results may be subjected to unneeded antibiotic treatment and an extended hospital stay, putting them at risk for further adverse events.
About Kurin, Inc.
Kurin, a certified Minority Business Enterprise (MBE), is focused on the design, development, manufacture, marketing, and sale of products that help healthcare providers reduce contaminated blood cultures. San Diego-based Kurin has received FDA 510(k) market clearance. For more information, visit the website at www.kurin.com.
View source version on businesswire.com:https://www.businesswire.com/news/home/20180717005141/en/
CONTACT: Kurin, Inc.
Matt Heindel, 858-752-9514
KEYWORD: UNITED STATES NORTH AMERICA CALIFORNIA
INDUSTRY KEYWORD: HEALTH HOSPITALS INFECTIOUS DISEASES MEDICAL DEVICES NURSING GENERAL HEALTH
SOURCE: Kurin, Inc.
Copyright Business Wire 2018.
PUB: 07/17/2018 06:00 AM/DISC: 07/17/2018 06:01 AM